MedTrace Logo

Phase I Study of ICP-332 in Healthy Subjects

NCT06530966 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-14

No results posted yet for this study

Summary

A multiple ascending dose phase I study of ICP-332 in healthy subjects

Conditions

  • Healthy Subjects

Interventions

DRUG

ICP-332 Tablets

Eligible patients will receive ICP-332 tablets orally as per the protocol

DRUG

ICP-332 Placebo Tablets

Eligible patients will receive ICP-332 placebo tablets orally as per the protocol

Sponsors & Collaborators

  • InnoCare Pharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-23
Primary Completion
2024-11-08
Completion
2024-11-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06530966 on ClinicalTrials.gov